Samuel S Engel

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4521105/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Efficacy and safety of the addition of sitagliptin to treatment of youth with type 2 diabetes and inadequate glycemic control on metformin without or with insulin. Pediatric Diabetes, 2022, 23, 183-193.	2.9	14
2	A randomized clinical trial of the efficacy and safety of sitagliptin as initial oral therapy in youth with type 2 diabetes. Pediatric Diabetes, 2022, 23, 173-182.	2.9	13
3	A randomized, placeboâ€controlled trial to assess the efficacy and safety of sitagliptin in J apanese patients with type 2 diabetes and inadequate glycaemic control on ipragliflozin. Diabetes, Obesity and Metabolism, 2021, 23, 1342-1350.	4.4	2
4	A randomized, placeboâ€controlled study to evaluate the efficacy and safety of adding omarigliptin to insulin therapy in Japanese patients with type 2 diabetes and inadequate glycaemic control. Diabetes, Obesity and Metabolism, 2021, 23, 1242-1251.	4.4	4
5	Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes and inadequate glycaemic control on sitagliptin. Diabetes, Obesity and Metabolism, 2021, 23, 2099-2108.	4.4	5
6	Efficacy and Safety of Sitagliptin Compared with Dapagliflozin in People ≥ 65 Years Old with Type 2 Diabetes and Mild Renal Insufficiency. Diabetes Therapy, 2020, 11, 2419-2428.	2.5	3
7	Progression of glucoseâ€lowering diabetes therapy in TECOS. Endocrinology, Diabetes and Metabolism, 2019, 2, e00053.	2.4	7
8	Efficacy and safety of sitagliptin added to treatment of patients with type 2 diabetes inadequately controlled with premixed insulin. Diabetes, Obesity and Metabolism, 2019, 21, 408-411.	4.4	2
9	Doubleâ€blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidaseâ€4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT†Study. Diabetes, Obesity and Metabolism, 2019, 21, 781-790.	4.4	19
10	Doubleâ€blind, randomized clinical trial assessing the efficacy and safety of early initiation of sitagliptin during metformin uptitration in the treatment of patients with type 2 diabetes: The CompoSITâ€M study. Diabetes, Obesity and Metabolism, 2019, 21, 1128-1135.	4.4	7
11	Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The <scp>VERTIS FACTORIAL</scp> randomized trial. Diabetes, Obesity and Metabolism, 2018, 20, 1111-1120.	4.4	121
12	Characteristics of Elderly Patients Initiating Sitagliptin or Non-DPP-4-Inhibitor Oral Antihyperglycemic Agents: Analysis of a Cross-Sectional US Claims Database. Diabetes Therapy, 2018, 9, 309-315.	2.5	7
13	Impact of differing glucoseâ€lowering regimens on the pattern of association between glucose control and survival. Diabetes, Obesity and Metabolism, 2018, 20, 821-830.	4.4	9
14	Efficacy and Safety of Sitagliptin in Hispanic/Latino Patients with Type 2 Diabetes: A Pooled Analysis from Ten Randomized, Placebo-Controlled Phase 3 Clinical Trials. Diabetes Therapy, 2018, 9, 1581-1589.	2.5	3
15	Sex differences in management and outcomes of patients with type 2 diabetes and cardiovascular disease: A report from TECOS. Diabetes, Obesity and Metabolism, 2018, 20, 2379-2388.	4.4	29
16	A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: The CompoSITâ€R study. Diabetes, Obesity and Metabolism, 2018, 20, 2876-2884.	4.4	33
17	Randomized clinical trial comparing the efficacy and safety of treatment with the onceâ€weekly dipeptidyl peptidaseâ€4 (<scp>DPP</scp> â€4) inhibitor omarigliptin or the onceâ€daily <scp>DPP</scp> â€4 inhibitor sitagliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Diabetes. Obesity and Metabolism. 2017, 19, 394-400	4.4	23
18	Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). Diabetes Care, 2017, 40, 494-501.	8.6	50

SAMUEL S ENGEL

#	Article	IF	CITATIONS
19	Safety of sitagliptin in patients with type 2 diabetes and chronic kidney disease: outcomes from TECOS. Diabetes, Obesity and Metabolism, 2017, 19, 1587-1593.	4.4	24
20	Hypoglycaemia seriousness and weight gain as determinants of cardiovascular disease outcomes among sulfonylurea users. Diabetes, Obesity and Metabolism, 2017, 19, 1425-1435.	4.4	39
21	A randomized, placebo―and sitagliptinâ€controlled trial of the safety and efficacy of omarigliptin, a onceâ€weekly dipeptidyl peptidaseâ€4 inhibitor, in <scp>J</scp> apanese patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2017, 19, 1602-1609.	4.4	19
22	A randomized clinical trial of the safety and efficacy of sitagliptin in patients with type 2 diabetes mellitus inadequately controlled by acarbose alone. Current Medical Research and Opinion, 2017, 33, 693-699.	1.9	10
23	A Randomized, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Adding Omarigliptin to Antihyperglycemic Therapies in Japanese Patients with Type 2 Diabetes and Inadequate Glycemic Control. Diabetes Therapy, 2017, 8, 793-810.	2.5	5
24	Sitagliptin added to stable insulin therapy with or without metformin in Chinese patients with type 2 diabetes. Journal of Diabetes Investigation, 2017, 8, 321-329.	2.4	12
25	A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus. Cardiovascular Diabetology, 2017, 16, 112.	6.8	78
26	Assessing occurrence of hypoglycemia and its severity from electronic health records of patients with type 2 diabetes mellitus. Diabetes Research and Clinical Practice, 2016, 121, 192-203.	2.8	52
27	Randomized clinical trial of the safety and efficacy of sitagliptin and metformin coâ€administered to Chinese patients with type 2 diabetes mellitus. Journal of Diabetes Investigation, 2016, 7, 727-736.	2.4	23
28	Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS. Diabetes Care, 2016, 39, 2304-2310.	8.6	142
29	Prevalence and co-prevalence of comorbidities among patients with type 2 diabetes mellitus. Current Medical Research and Opinion, 2016, 32, 1243-1252.	1.9	315
30	Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine, 2015, 373, 232-242.	27.0	2,188
31	Characterization of Sitagliptin Use in Patients with Type 2 Diabetes and Chronic Kidney Disease by Cross-Sectional Analysis of a Medical Insurance Claims Database. Diabetes Therapy, 2015, 6, 627-634.	2.5	5
32	A Randomized Clinical Trial to Evaluate the Efficacy and Safety of Co-Administration of Sitagliptin with Intensively Titrated Insulin Glargine. Diabetes Therapy, 2015, 6, 127-142.	2.5	37
33	Comparison of Treatment with Sitagliptin or Sulfonylurea in Patients with Type 2 Diabetes Mellitus and Mild Renal Impairment: A Post Hoc Analysis of Clinical Trials. Diabetes Therapy, 2015, 6, 29-40.	2.5	10
34	Safety of Sitagliptin in Elderly Patients with Type 2 Diabetes: A Pooled Analysis of 25 Clinical Studies. Drugs and Aging, 2014, 31, 203-214.	2.7	33
35	Impact of time to treatment intensification on glycemic goal attainment among patients with type 2 diabetes failing metformin monotherapy. Journal of Diabetes and Its Complications, 2014, 28, 831-835.	2.3	24
36	Safety and Tolerability of Sitagliptin in Type 2 Diabetes: Pooled Analysis of 25 Clinical Studies. Diabetes Therapy, 2013, 4, 119-145.	2.5	109

#	Article	IF	CITATIONS
37	Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis. Cardiovascular Diabetology, 2013, 12, 3.	6.8	84
38	The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes* ^{â€} . Journal of Diabetes, 2012, 4, 227-237.	1.8	56
39	Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. BMC Endocrine Disorders, 2010, 10, 7.	2.2	234